Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (September 2016)
24 slides from Rennova Health's investor presentation, September 2016
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
Nasdaq: RNVA Diagnostics and Supportive Software Solutions to Healthcare Providers Sept 2016
Slide 2: Forward-Looking Statements and Non-GAAP Information
Forward-Looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 3: Who We Are
Who We Are Healthcare is Being Transformed Headquartered in West Palm Beach, Florida Rennova Health (Nasdaq RNVA, RNVAZ) is a healthcare service provider offering a suite of integrated services including but not limited to, Diagnostics, EHR, Laboratory Information Systems software, cancer diagnostic
Slide 4: Highlights
Highlights • Approximately $8M invested in our Laboratories in 2014 and 2015, with no further significant investment required to enable substantial increases in diagnostics testing. • Approximately $5M invested in our software products in 2014 and 2015. Investment is ongoing but products are complet
Slide 5: Single Source Solution for Medical Providers
Single Source Solution for Medical Providers • The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have created a need fo
Slide 6: Single Source Solution for Medical Providers
Single Source Solution for Medical Providers Our core business is diagnostics: Historically >90% of our revenue has been derived from diagnostics That is changing: Clinical Lab Services 5 Clinical Laboratories Single Source Solution Revenue Software Cycle Solutions Proprietary Lab ordering and Manag
Slide 7: Recent Developments
Recent Developments Corporate • Received net proceeds of approximately $7.3M in July from a public offering of common shares and warrants • Exchanged all Series C Convertible Preferred Stock and 6,451,611 RNVAW warrants with certain downside protection to Series G Convertible Preferred Stock and new
Slide 8: Recent Developments
Recent Developments Clinical Laboratory Operations Segment • Reported increased revenue in the 2nd quarter of 2016 compared to the 1st quarter • Continue to experience the benefits of our stance on compliance in light of the current disruption in the toxicology sector – a major focus of our Clinical
Slide 9: 2015 Accomplishments
2015 Accomplishments Completed Lab Development Supportive Software Development Nasdaq listing 9
Slide 10: Our Target Markets
Our Target Markets Drug and Alcohol Rehabilitation • Large and growing number of facilities in a fragmented market • Total market size estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* • Market growth from high de
Slide 11: Our Target Markets
Our Target Markets Pain Management Sector • Large and growing number of clinics in a fragmented market • Total Market Size – estimated at $2-$4 Billion***** • Private clinics in the U.S. estimated between 1,500 and 2,500******** • More than 6,800 doctors specialize in pain management and more than 6
Slide 12: Rennova Health Licensing Map
Rennova Health Licensing Map 12
Slide 13: Our Payers
Our Payers • Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 • Applied for Medicaid Licenses in 34 States • As of September 21, 2016, we possess Medicaid Licenses in 23 States • Current Third Party Insurance Payer Contracts • Blue Shield of California • Coventry (Nationa
Slide 14: Strategy
Strategy 14
Slide 15: Long Term Strategy
Long Term Strategy Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology-focused company to: 1. A significant and diverse diagnostics business 2. Offering supportive software solutions that add value by gener
Slide 16: 2016 Goals
2016 Goals • Strengthen Core Diagnostic Business • Capitalize on recent disruption in toxicology sector • Increase Clinical testing • Grow Pharmacogenomics testing with Genomas • Launch DTC (direct to consumer) testing • Accelerate Growth and/or Launch: • Supportive software product sales (EHR in Re
Slide 17: Online Training Program Launch to Deliver Increased Sales
Online Training Program Launch to Deliver Increased Sales Program Objectives: • Ensure consistency in messaging and information • Provide effective and easy to use platform • Make information accessible anytime and from anywhere • Enable opportunity for monitoring and assessment Initially for sales
Slide 18: Business Development Opportunities
Business Development Opportunities Epinex Diagnostics, Inc. Genomas Diabetes and rapid diagnostic Genomics based diagnostics - tests for providers & consumers drug management solution 18
Slide 19: History in Numbers
History in Numbers ($000’s) 70,000 59,429 60,000 50,000 41,889 37,877 40,000 30,000 23,030 19,749 20,000 14,775 10,000 4,933 1,386 2,217 0 (10,000) (9,980) (20,000) 2013 2014 2015 1st half 2015 1st half 2016 Adjusted Revenues Adjusted EBITDA 19
Slide 20: Select Income Statement Items
Select Income Statement Items 6 Months 6 Months (in thousands) 2013 2014 2015 2015 2016 GAAP Net Revenue $ 41,889 $ 57,928 $ 18,393 $ 23,030 $ 4,933 Reserve for Aged Accounts Receivable - 1,501 19,494 - - Adjusted Revenues $ 41,889 $ 59,429 $ 37,887 $ 23,030 $ 4,933 GAAP Pretax Income (Loss) $ 13,82
Slide 21: Capitalization at September 22, 2016
Capitalization at September 22, 2016 As of September 22, 2016 Common Shares Outstanding 53,670,931 Common shares underlying Series G Preferred Stock 21,758,222 Dilutive Potential Shares: Stock Options @ WAVG ex. $4.19 22,599,174 Convertible Debt 1,760,000 Warrants @ WAVG ex. $0.44 35,146,062 Total D
Slide 22: Rennova Management
Rennova Management Seamus Lagan • 20 years experience in the restructuring, development and CEO management of startup and small companies Jason Adams • CFO in behavorial health sector and Senior Financial CFO Management of public companies Victoria Nemerson, Esq. • 25 years experience as a trial and
Slide 23: Board of Directors
Board of Directors Thomas Mika • 10 years as Chairman and CEO of a Nasdaq listed Company • Oversaw a number of public offerings Chairman of Rennova, CEO of CollabRx (subsidiary) • Bachelor of Science degree in Microbiology, MBA Harvard Seamus Lagan • 20 years experience in the restructuring, develop
Slide 24: Highlights
Highlights • Approximately $8M invested in our Laboratories in 2014 and 2015, with no further significant investment required to enable substantial increases in diagnostics testing. • Approximately $5M invested in our software products in 2014 and 2015. Investment is ongoing but products are complet
Rennova Health — Investor Presentation (September 2016) on 6ix